Terminated trial tests new combo for tough lung cancers
NCT ID NCT05141357
Summary
This study tested whether adding a new oral drug called HBI-8000 to an existing immunotherapy (pembrolizumab) could help control advanced non-small cell lung cancer. It was designed for adults with a specific biomarker (PD-L1 ≥1%) who had limited prior treatment. The trial was terminated early after enrolling only 5 participants, so its effectiveness remains unknown.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CBCC Global Research, Inc at Comprehensive Blood and Cancer Center
Bakersfield, California, 93309, United States
-
Cotton O'Neil Clinical Research Center
Topeka, Kansas, 66606, United States
-
Frederick Health-JMSCI
Frederick, Maryland, 21702, United States
-
Hematology Oncology Associates Of The Treasure Coast
Port Saint Lucie, Florida, 34952, United States
-
Midewestern Regional Medical Center, LLC
Zion, Illinois, 60099, United States
-
Southeastern Regional Medical Center
Newnan, Georgia, 30265, United States
-
Western Regional Medical Center
Goodyear, Arizona, 85338, United States
Conditions
Explore the condition pages connected to this study.